Company intelligence / Profile preview
Sequence LifeScience
San Antonio, Texas, United Statessequencelifesci.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Sequence LifeScience is conducting a multicenter prospective matched controls clinical trial investigating placental-derived allografts for the treatment of diabetic foot ulcers. The trial, expected to begin recruiting in July 2025, seeks to generate robust comparative data on healing rates and safety using a novel trial design with historic matched controls. Prior studies on placental membranes as wound covers show promising benefits in wound healing, antimicrobial, and anti-inflammatory activity.
- Therapeutic areas
- EndocrinologyDermatologyOther
- Modalities
- Biologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
SerenaGroup Inc.
Beyond the preview
Go deeper on Sequence LifeScience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sequence LifeScience.